Scholars Central

OtherPublished 22 Jul 2016

Outcomes of novel trials for cancer cachexia

Authors: Rony Dev, Egidio Del Fabbro, Eduardo Bruera

Clinical Investigation

Volume 4 · Issue 3 · Pages 247–257

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cancer cachexia is a multifactorial syndrome characterized by involuntary loss of skeletal muscle and fat, reduced quality of life and decreased survival. Unlike starvation, weight loss cannot be fully reversed by increasing caloric intake. Interventions, such as nutritional counseling or currently available appetite stimulants such as megestrol acetate have limited benefits. Recently, there has been an increase in the understanding of the pathophysiology contributing to weight loss in patients with cancer. Clinical trials of various pharmacological therapies targeting the underlying pathophysiological derangements contributing to cancer cachexia are underway. A personalized approach may be needed for managing patients with anorexia–cachexia syndrome in conjunction with the best supportive care. The following narrative review will highlight novel therapies being investigated for the treatment of cancer cachexia, which can be used as a single-agent or combined in multimodal therapy.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Investigation
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Rony Dev”
  • BylineArticles whose byline prints “Egidio Del Fabbro”
  • BylineArticles whose byline prints “Eduardo Bruera”